Abbvie Inc Stock Price, News & Analysis

Allergan Aesthetics (NYSE: ABBV) launched the Faces of Natrelle® Testimonial Program on Feb 3, 2026, inviting U.S. women who had Natrelle® breast augmentation or reconstruction at age 22+ to submit photos, videos, and testimonials for possible publication.

Augmentation participants who are Allē members may receive five $100 Allē gift cards if selected and approved; reconstruction patients are encouraged to share but are not eligible for compensation. Important safety information and a Boxed Warning for breast implants are reiterated, including BIA-ALCL risk and recommended imaging timelines.

AbbVie (NYSE: ABBV) submitted applications to the FDA and EMA for upadacitinib (RINVOQ®) 15 mg once daily to treat adults and adolescents with non-segmental vitiligo. The filings are supported by Phase 3 Viti-Up results showing co-primary endpoints: T-VASI 50 and F-VASI 75 at week 48.

If approved, upadacitinib would be the first systemic therapy for vitiligo, addressing a high unmet need in a disease with substantial psychosocial burden and unpredictable progression.

AbbVie (NYSE: ABBV) launched Love in Mind™ on January 29, 2026, an educational initiative about the emotional impact of migraine on dating and romantic relationships. A Harris Poll of 606 adults found 89% struggle to be present, 51% canceled dates (avg. 8 times/year), and 78% push past pain to be intimate. Country artist Jessie James Decker shares her personal experience; relationship guidance is offered by Nedra Glover Tawwab. Resources and full survey findings are available at LoveInMind.com.

Allergan Aesthetics (NYSE: ABBV) will present nine e-posters and host symposia at IMCAS World Congress, Jan 29–31, 2026, in Paris showcasing facial injectable data across TrenibotulinumtoxinE, onabotulinumtoxinA (BOTOX Cosmetic), hyaluronic acid fillers, and a biostimulatory hybrid filler.

Pooled Phase 3 TrenibotulinumtoxinE results report rapid onset and short-duration effects; two Phase 4 onabotulinumtoxinA studies show long-term use benefits and patient satisfaction with natural outcomes. Allergan will highlight multimodal AA Signature™ approaches and live injection educational sessions.

AbbVie (NYSE: ABBV) reported topline Phase 3 EPCORE DLBCL-1 results for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) on Jan 16, 2026. The trial enrolled 483 patients (73% with ≥2 prior lines) and showed improved progression-free survival (PFS) with HR 0.74 (95% CI 0.60–0.92). Improvements were also seen in complete response rate, duration of response, and time to next treatment. The study did not show a statistically significant overall survival benefit (OS HR 0.96; 95% CI 0.77–1.20). Safety was described as consistent with known epcoritamab profile. AbbVie and Genmab plan regulatory discussions and future data presentation.

AbbVie (NYSE: ABBV) announced a voluntary three-year agreement with the Trump administration on January 12, 2026 to expand access and affordability while protecting U.S. pharmaceutical investment. AbbVie will provide low prices in Medicaid, expand direct-to-patient offerings through TrumpRx for medicines used by millions (including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID), and commit $100 billion in U.S. research, development and capital investments, including manufacturing, over the next decade. The agreement includes an exemption from tariffs and future pricing mandates; further terms remain confidential.

AbbVie (NYSE: ABBV) and RemeGen announced an exclusive licensing agreement dated Jan. 12, 2026 for RC148, a PD-1/VEGF bispecific antibody in development for multiple advanced solid tumors including NSCLC and colorectal cancer.

Under the deal, AbbVie gains exclusive rights to develop, manufacture, and commercialize RC148 outside the Greater China territory. RemeGen received a $650 million upfront payment and is eligible for up to $4.95 billion in development, regulatory, and commercial milestones, plus tiered double-digit royalties on net sales outside Greater China. Early clinical studies reported initial favorable antitumor activity for RC148 in combination with an ADC; AbbVie intends to explore combinations with its ADC programs including telisotuzumab adizutecan (Temab-A).

AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.

AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.

West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.

The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.

SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.